Tenecteplase or Alteplase

Phase 3Protein / enzyme

IInsel Gruppe AG, University Hospital Bern

Tenecteplase or Alteplase is one of 36 small molecule programs targeting Ischemic stroke. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ischemic StrokeRecruiting

Ischemic StrokePhase 3

Recruiting

Competition

Competitive Landscape

119 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Tnkase

Roche

Phase 3

17 2

Atorvastatin Calcium

Merck & Co.

Phase 3

1 3

Butylphthalide

PPeking Union Medical College Hospital

Phase 3

3 4

Aggrastat

MMedicure

Phase 3

4 5

Edaravone Dexborneol

SSimcere Pharmaceutical Co., Ltd

Phase 3

10 6

Tenecteplase or Alteplase

IInsel Gruppe AG, University Hospital Bern

Phase 3

2 7

Proamatine

Takeda

Preclinical

2 8

Levaquin

WWim Janssens

Preclinical

3 9

Tylenol

KKenvue Brands

Preclinical

1 10

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Ischemic Stroke

NCT06556446

Q2 2029

ApprovedRecruiting

Ischemic Stroke

NCT06571149

Clinical

Trials by Indication[1]

Ischemic stroke2 trials

Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants

Recruiting·IInsel Gruppe AG, University Hospital Bern··NCT06556446·2,800 enrolled

Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke on Treatment With Direct Oral Anticoagulants: DO-IT - The DOAC Intravenous Thrombolysis Trial

Recruiting·IInsel Gruppe AG, University Hospital Bern·Approved·NCT06571149·906 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Tenecteplase or Alteplase. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tenecteplase or Alteplase compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tenecteplase or Alteplase. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Insel Gruppe AG, University Hospital Bern company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: IInsel Gruppe AG, University Hospital Bern

Tenecteplase or Alteplase

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2029

Trials by Indication[1]

Ischemic stroke2 trials

References

Drug Info

Quick Facts

Related News